These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30709830)

  • 41. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
    Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short- and Long-Term Management of an Acute Pustular Psoriasis Flare: A Case Report.
    Georgakopoulos JR; Ighani A; Yeung J
    J Cutan Med Surg; 2017; 21(5):452-456. PubMed ID: 28535721
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
    Papp KA; Kaufmann R; Thaçi D; Hu C; Sutherland D; Rohane P
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e376-83. PubMed ID: 23030767
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ▼ Apremilast for psoriasis and psoriatic arthritis.
    Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Apremilast in psoriasis - a prospective real-world study.
    Vujic I; Herman R; Sanlorenzo M; Posch C; Monshi B; Rappersberger K; Richter L
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):254-259. PubMed ID: 28925560
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A cost-effectiveness and budget impact analysis of apremilast in patients with psoriasis in the Italian setting.
    Barbieri M; Loconsole F; Migliore A; Capri S
    J Med Econ; 2020 Apr; 23(4):362-370. PubMed ID: 31856619
    [No Abstract]   [Full Text] [Related]  

  • 49. Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis.
    Ohata C; Ohyama B; Kuwahara F; Katayama E; Nakama T
    J Dermatolog Treat; 2019 Jun; 30(4):383-386. PubMed ID: 30221571
    [No Abstract]   [Full Text] [Related]  

  • 50. Long-term 52-week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series.
    Ighani A; Georgakopoulos JR; Shear NH; Walsh S; Yeung J
    Br J Dermatol; 2019 Jan; 180(1):211-212. PubMed ID: 30120892
    [No Abstract]   [Full Text] [Related]  

  • 51. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A; Gladman DD; Edwards CJ; Schett G; Guerette B; Delev N; Teng L; Paris M; Mease PJ
    Arthritis Res Ther; 2019 May; 21(1):118. PubMed ID: 31077258
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
    Nash P; Ohson K; Walsh J; Delev N; Nguyen D; Teng L; Gómez-Reino JJ; Aelion JA;
    Ann Rheum Dis; 2018 May; 77(5):690-698. PubMed ID: 29343507
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study.
    Augustin M; Kleyn CE; Conrad C; Sator PG; Ståhle M; Eyerich K; Radtke MA; Bundy C; Mellars L; Greggio C; Cordey M; Koscielny V; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):123-134. PubMed ID: 32279378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
    Armstrong A; Levi E
    J Drugs Dermatol; 2017 Dec; 16(12):1240-1245. PubMed ID: 29240859
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug survival of apremilast in a real-world setting.
    Kishimoto M; Komine M; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2019 Jul; 46(7):615-617. PubMed ID: 31180150
    [TBL] [Abstract][Full Text] [Related]  

  • 56. One stone, two birds: Improvement of early-onset vitiligo under apremilast in a patient with plaque psoriasis.
    Plachouri KM; Kyriakou G; Chourdakis V; Georgiou S; Grafanaki K
    Dermatol Ther; 2019 Sep; 32(5):e13064. PubMed ID: 31414705
    [No Abstract]   [Full Text] [Related]  

  • 57. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
    J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.
    Takamura S; Sugai S; Taguchi R; Teraki Y
    J Dermatol; 2020 Mar; 47(3):290-294. PubMed ID: 31867729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
    Pincelli C; Schafer PH; French LE; Augustin M; Krueger JG
    J Drugs Dermatol; 2018 Aug; 17(8):835-840. PubMed ID: 30124722
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.
    Bagel J; Nelson E; Keegan BR
    J Drugs Dermatol; 2017 Oct; 16(10):957-962. PubMed ID: 29036248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.